Evaluation of Non-Surgical Periodontal Treatment on Salivary Biomarkers in Patients Undergoing Bisphosphonate Therapy

Objectives: Similar mechanisms and risk factors are considered to involve in the progression of osteoporosis and periodontitis. Bisphosphonates present anti-inflammatory activity and inhibit the release of proinflammator cytokines. Therefore their use as an adjunct to non-surgical periodontal treatment has been introduced. This study aimed to evaluate the effect of non-surgical periodontal treatment and medical treatment of osteoporosis by bisphosphonates on the clinical outcomes and salivary levels of interleukine- 1 beta (IL-1β) , interleukine-17, (IL-17) and 8-Hydroxy-deoxyguanosine (8-OHdG). Materials and Methods: 25 postmenopausal women with periodontitis and osteoporosis (group 1), 25 systemically healthy patients with periodontitis (group 2) and 25 systemically and periodontally healthy individuals (group 3) were enrolled in this study. In the group 1, patients who used systemic alendronate once weekly (70 mg) for at least 3 months, were included. Clinical parameters (plaque index, gingival index, bleeding on probing, probing depth and clinical attachment loss) and saliva samples were analyzed at baseline, 1 month and 3 months after non-surgical therapy. Results: All clinical parameters were significantly higher in osteoporotic patients than in the systemically healthy group (p